Claritas HealthTech has spun off its nuclear medicine division into a separate company named Claritas NucMed Technologies.
Claritas NucMed was established and registered in the U.K. and will focus on the global commercialization, delivery, and deployment of its nuclear medicine suite of software solutions for PET and SPECT, the company said.
Claritas received clearance from the U.S. Food and Drug Administration (FDA) to market its Claritas iPET image processing software in 2022. Its products also include Claritas iSPECTcardiac, software that reduces scan time and/or contrast dosage by 50% in SPECT imaging, according to the firm.
